ArticleJournal of thoracic disease2018
Risk for cardiovascular disease in patients with nontuberculous mycobacteria treated with macrolide.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease.Internal and emergency medicine · 2024Article
- Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication ofJournal of clinical medicine · 2023Review
- Journal Club - Bronchiectasis/COPD Overlap: Syndrome Versus Treatable Trait?Chronic obstructive pulmonary diseases (Miami, Fla.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMacrolide antibiotics are the most important pharmacological agents for the treatment of nontuberculous mycobacterial disease. We investigated the incidence of acute cardiovascular events in patients taking macrolides for nontuberculous mycobacterial disease and determined the difference in risk between clarithromycin and azithromycin.
methodsA population-based retrospective cohort study was conducted in South Korea using the Health Insurance Review and Assessment Service database. Patients ≥40 years treated with macrolide for nontuberculous mycobacteria (NTM) between 2011 and 2015 were examined. The primary outcome was hospitalization or emergency department visit for cardiovascular disease along with acute myocardial infarction, cerebrovascular disease, and cardiac arrhythmia. The standardized incidence ratio (SIR) for cardiovascular disease was calculated by comparing the patients with the general population in the year 2013. Cox proportional hazard model was used to compare the risk between clarithromycin and azithromycin.
resultsIn total, 16,525 patients with nontuberculous mycobacterial disease treated with macrolide were included; 13,870 received clarithromycin and 2,655 received azithromycin. The cardiovascular incidence was significantly higher in patients with nontuberculous mycobacterial disease than in the age- and sex-stratified general population [SIR, 1.44; 95% confidence interval (CI), 1.27-1.61]. The risk was not significantly different between patients treated with clarithromycin and azithromycin (adjusted hazard ratio, 0.90; 95% CI, 0.65-1.24).
conclusionsThe incidence of cardiovascular disease was significantly higher in patients treated with macrolide for nontuberculous mycobacterial disease than in the general population. This risk was not different between patients treated with clarithromycin and azithromycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.